Clinical Trials on Blood Coagulation Disorders

Total 201553 results

Real Fundación Victoria Eugenia
Universidad de Murcia; Medtep Inc.

Unknown

Effectiveness of the uPatient Platform in Prophylactic Treatment in Hemophilia (uPatient)

Haemophilia
Real Fundación Victoria Eugenia
Medtep Inc.

Unknown

Validation of a Specific Measure for Assessment of Compliance With Treatment in Patients With Hemophilia

Haemophilia

Spain
Universidad Católica San Antonio de Murcia

Unknown

Assessment of Proprioceptive and Functional Characteristics in Patients With Hemophilia (HE-BALANCE)

Hemophilia

Spain
Novo Nordisk A/S

Completed

A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B (paradigm™7)

Congenital Bleeding Disorder | Haemophilia B

United States, Switzerland, Germany
Novo Nordisk A/S

Completed

Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A (pathfinder™2)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Denmark, Netherlands, Sweden, Spain, Germany, Switzerland, Taiwan, Japan, United Kingdom, Croatia, Italy, Malaysia, Brazil, Australia, Hungary, Israel, Turkey, Puerto Rico, Norway, Korea, Republic of, Bulgaria, Russian...
Novo Nordisk A/S

Completed

Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (guardian TM 7)

Congenital Bleeding Disorder | Haemophilia A

China
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects (guardian™1)

Congenital Bleeding Disorder | Haemophilia A

United States, Spain, Germany, Switzerland, Serbia, Taiwan, United Kingdom, Croatia, Italy, Malaysia, Brazil, Japan, Denmark, Hungary, Israel, Turkey, Russian Federation, Former Serbia and Montenegro
Sanofi

Recruiting

A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab

Hemophilia A

Taiwan
Tulane University
Genentech, Inc.

Recruiting

Factor IX as Adjunctive Therapy to Emicizumab (EMIX)

Hemophilia A

United States
Assistance Publique Hopitaux De Marseille

Recruiting

Objective and Perceived Health Status of Elderly People With Moderate or Severe Haemophilia in France: an Ancillary Study of the FranceCoag Registry (SENIORHEMO)

Moderate or Serious Haemophilia

France
Octapharma

Recruiting

Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency

Congenital Fibrinogen Deficiency

Germany
Enzyre B.V.
Instytut Hematologii i Transfuzjologii, Warschau, Poland

Completed

Real-life Clinical FEIBA Samples Measured Using the Version A of the HemA EnzySystem

Hemophilia A | Hemophilia A With Inhibitor

Poland
Pfizer

Active, not recruiting

Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults (AFFINE)

Hemophilia A

Spain, Taiwan, Australia, United States, Japan, France, Turkey, Germany, Korea, Republic of, United Kingdom, Saudi Arabia, Canada, Greece, Sweden, Brazil, Italy
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors (HAVEN 7)

Severe Hemophilia A

Canada, United States, United Kingdom, Belgium, Australia, Austria, Brazil, France, Germany, Israel, Italy, South Africa, Spain, Turkey
Swedish Orphan Biovitrum
Cerner Enviza

Completed

rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia A

Hemophilia A With Inhibitor

France, Ireland, Italy, Norway, Germany, Kuwait, Saudi Arabia, Switzerland
BioMarin Pharmaceutical

Active, not recruiting

Gene Therapy Study in Severe Haemophilia A Patients (270-201)

Severe Haemophilia A

United Kingdom
Bayer

Terminated

A Study to Learn More About Treatment With Damoctocog Alfa Pegol, How it is Used in Every Day Practice ("Real-World"), and How Satisfied People Who Receive Damoctocog Alfa Pegol Are in United States (US) Hemophilia Treatment Centers (REAL)

Hemophilia A

United States
AryoGen Pharmed Co.

Completed

rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study

Severe Hemophilia A

Iran, Islamic Republic of
Bayer

Completed

Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis (TAURUS)

Hemophilia A, Congenital

Slovenia, Italy, Germany, France, United States, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Taiwan
Margaret Ragni
Health Resources and Services Administration (HRSA)

Terminated

The Hemophilia Inhibitor Prevention Trial

Hemophilia A Without Inhibitor

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age

Hemophilia A
Grifols Biologicals, LLC

Completed

Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A

Severe Hemophilia A

Poland
Prof. Dr. Dr. Thomas Hilberg
Pfizer

Completed

iT-based Sports Therapy Application in Haemophilia (iT-BaSTAH)

Sports Physical Therapy | Haemophilia

Germany
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A

Hemophilia A

United States, France, Italy, Spain, Netherlands, United Kingdom, Ireland, New Zealand, Poland, Australia, Germany, Brazil, Sweden, Canada
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

Hemophilia A With Inhibitors

United States, Spain, Canada, Belgium, France, Bulgaria, Italy, United Kingdom, Japan, Germany
Grifols Therapeutics LLC
Grifols Biologicals, LLC

Terminated

Alphanate in Immune Tolerance Induction Therapy

Hemophilia A, Congenital

United States, Spain, Italy, India, Canada, Russian Federation
Bio Products Laboratory

Completed

Registry Study of COAGADEX® Patients With Moderate or Severe Hereditary Factor X Deficiency Undergoing Major Surgery

Factor 10 Deficiency

United States
Pfizer

Completed

PF-06741086 Long-term Treatment in Severe Hemophilia

Hemophilia A or B

Poland, Switzerland, South Africa, United States, Croatia, Brazil, Chile
Octapharma

Completed

Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients

Severe Hemophilia A

Canada, United States, France, Spain, Ukraine, United Kingdom, Belarus, Georgia, Germany, India, Italy, Moldova, Republic of, Morocco, Poland, Portugal, Russian Federation, Slovenia
Octapharma

Completed

Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A

Severe Hemophilia A

Bulgaria, Poland, Hungary, Romania, Russian Federation
Bioverativ Therapeutics Inc.

Completed

Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A (ASPIRE)

Hemophilia A

United States, Canada, Italy, Australia, Austria, Belgium, Brazil, France, Germany, Hong Kong, India, Ireland, Israel, Japan, Netherlands, New Zealand, Poland, South Africa, Spain, Sweden, Switzerland, United Kingdom
Bioverativ Therapeutics Inc.

Completed

Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A

Severe Hemophilia A

United States, Hong Kong, Israel
Cliniques universitaires Saint-Luc- Université...
World Federation of Hemophilia

Completed

Non Substitutive Strategies to Improve Haemophilia Care in Developing Countries. Experience in Ivory Coast.

Haemophilia | Developing Countries

Côte D'Ivoire
Pfizer

Completed

BeneFIX Drug Use Results Survey [All-Case Surveillance]

Hemophilia B

Japan
Healthcare Innovation Technology Lab
Bayer

Unknown

Hemophilia Mobile App Usability Pilot

Hemophilia

United States
Octapharma

Completed

Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap

Congenital Fibrinogen Deficiency | Afibrinogenemia

Iran, Islamic Republic of, United States, Bulgaria, India, Switzerland, United Kingdom
Octapharma

Completed

Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A

Severe Haemophilia A

Austria, United Kingdom, Bulgaria, Hungary, Germany, Poland, Romania, Slovakia
Children's Hospital Los Angeles

Withdrawn

Individualizing Hemophilia Bypassing Agent Therapy Utilizing Thromboelastography

Hemophilia A With Inhibitors
Bloodworks
Oregon Health and Science University; Seattle Children's Hospital; Providence...

Unknown

Comparison of Ideal vs. Actual Weight Base Factor Dosing

Hemophilia A

United States
University of Pittsburgh
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A

Severe Hemophilia A

United States
Nara Medical University
Shire

Unknown

Basic Study of Combination Therapy Based on APCC-induced FVllI Activation in Hemophilia A Patients With Inhibitors

Hemophilia A With Inhibitor

Japan
Bayer

Completed

Prophylaxis Versus on Demand Treatment for Children With Hemophilia A

Hemophilia A

China
Skane University Hospital

Completed

Hemophilia Inhibitor Genetics Study (HIGS)

Hemophilia A With Inhibitor

Sweden
Turkish Society of Hematology

Unknown

Turkish Acquired Haemophilia Registry (EHEM)

Acquired Haemophilia

Turkey
New York Presbyterian Hospital
Manchester University NHS Foundation Trust

Terminated

International Immune Tolerance Study

Hemophilia A With Inhibitors

United States
Postgraduate Institute of Medical Education and...

Recruiting

Heparin Like Effect in Acute Variceal Bleeding

Coagulation Disorder | Cirrhosis, Liver | Variceal Hemorrhage

India
Takeda

Not yet recruiting

A Study of Recombinant Von Willebrand Factor (rVWF) (TAK-577) in Children With Severe Von Willebrand Disease (vWD)

Von Willebrand Disease (VWD)
VWD Connect Foundation

Recruiting

The Severe Von Willebrand Disease (sVWD) Patient Registry

VWD - Von Willebrand's Disease

United States
Assiut University

Not yet recruiting

Update in VWD Laboratory Diagnosis

VWD - Von Willebrand's Disease
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Recruiting

A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

Von Willebrand Disease (VWD)

United States, Italy, Spain, Netherlands, Turkey, France, Austria, Germany, Russian Federation

Clinical Trials on Blood Coagulation Disorders

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations